Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting
Abstract Highlights New Preclinical Data on Exosome-Based Delivery of PMOs for the Treatment of DMD-SAN DIEGO, Nov. 12, 2024 ...
Zacks.com on MSN5d
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?
Here is how Capricor Therapeutics (CAPR) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
The Globe and Mail1h
S&P Futures Tick Lower as Key U.S. Inflation Data Looms
December S&P 500 E-Mini futures (ESZ24) are trending down -0.19% this morning as investors held back from making big bets ahead of a crucial U.S. inflation report that could influence the Federal ...
labiotech1d
Six exosome therapy companies driving development in the field
Discover six exosome therapy companies developing these tiny extracellular vesicles to treat an array of diseases.
Oppenheimer Keeps Their Buy Rating on Catalyst Pharma (CPRX)
Oppenheimer analyst Leland Gershell maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...
Oppenheimer Sticks to Their Buy Rating for SAB Biotherapeutics (SABS)
Oppenheimer analyst Leland Gershell maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target ...
pharmaphorum1d
Capricor preps phase 3 for Duchenne cell therapy as it seeks a partner
Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease progression.
Seeking Alpha4d
CAPR Capricor Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.